SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Mutation R75T

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

There is one clinical trial.

Clinical Trials


1 A Randomized Trial of Comparing a Combination of Montelukast and Budesonide With Budesonide in Allergic Rhinitis

It is not proven unequivocally whether a combination of an intranasal corticosteroids (INS) and a cysteinyl leukotriene receptor antagonist has greater efficacy than INS in the treatment of severe allergic rhinitis (AR) . We performed a randomized, open-label study in 46 seasonal AR subjects receiving budesonide (BD, 256ug) plus montelukast (MNT, 10 mg) or BD alone (256ug) for 2 weeks. Visual analog scale (VAS) scores, nasal cavity volume (NCV), nasal airway resistance (NAR) and fractional exhaled nitric oxide (FeNO) were assessed before and at end of treatments as the primary treatment outcomes. Similarly, histamine, eosinophil cationic protein (ECP) and cysteinyl-leukotrienes (Cyslts) in nasal secretion and Th1/Th2 cells in nasal mucosa were evaluated as the secondary treatment outcomes.

NCT04077892 Allergic Rhinitis Drug: budesonide
MeSH: Rhinitis Rhinitis, Allergic
HPO: Allergic rhinitis Rhinitis

NAR was measured at 75 Pa point (R75T).. --- R75T ---

Primary Outcomes

Description: The participants were asked by one investigator to fill in a questioner detailing the presence of nasal and eye symptoms (including nasal congestion, rhinorrhea, nasal itching, sneezing and eye itching), and to score each symptom on a 0-10 cm scale; with 0 cm = no symptoms and 10 cm = most severe and bothersome symptom. The same investigator calculated both the individual symptom and the average of the sum of 5 AR symptoms scores, before and at the end of 14 days' treatment. Any subject with a mean score of < 4 cm at baseline was excluded from this study.

Measure: The change of subjective AR symptoms

Time: at baseline, 14 days

Secondary Outcomes

Description: Eccovision acoustic rhinometry was used to measure the nasal cavity volume (NCV) according to standardized recommendations. Measurements of nasal volume were made from the first 2 cm (V2), the first 4 cm (V4), from the first 6 cm (V6), from the segment between 0 and 5 cm (V0-5), and the segment between 0 and 7 cm (V0-7) of the nose. All measurements were performed three times by the same operator, and nasal volumes were calculated as the sum of both nostrils24. In the current study, the change in the nasal cavity volume was measured at 2-5 cm, as this seems to be an important variable for mucosal changes.24 Nasal airway resistance (NAR) was measured by anterior active rhinomanometry in a quiet room at temperature of 25°C and humidity of 70%. NAR was measured at 75 Pa point (R75T).

Measure: The change of objective examination: nasal patency

Time: at baseline, 14 days

Description: A nitric oxide analyser was used to measure exhaled nasal nitric oxide (nNO). Briefly, NO-free air was aspirated through the nasal cavity at a flow rate of 50 ml/s. The subject exhaled against the air-resistance, resulting in an intraoral pressure to close the velum and prevent mixture of oral and nasal gas. Nasal gas from this circuit was continuously routed in part directly into the analyser for determination of nNO, and the level of nNO(ppb) was calculated from a plateau lasting for at least 3s.

Measure: The change of Fractional Exhaled NO

Time: at baseline, 14 days


HPO Nodes


Rhinitis
Genes 97
DNAH9 GAS8 DNAH11 TNFSF11 SPAG1 ARMC4 EDARADD GAS2L2 CCDC151 SPINK5 CFAP300 ZMYND10 TCIRG1 SRP54 CFAP221 RFX5 IDUA DNAI2 DNAH1 RSPH4A TNFSF11 NME8 DNAAF4 CCDC65 DBH DNAAF5 CARMIL2 CFAP300 SNX10 FOXJ1 DNAI1 GFI1 CCNO ARMC4 RSPH1 RSPH1 CCDC39 STK36 RFXANK DNAL1 DNAH1 ZMYND10 LRRC6 RSPH3 RSPH9 RFXAP MS4A2 DRC1 RSPH9 CCDC103 DNAAF3 LRRC56 LRRC6 GAS8 IDUA CFAP298 CFAP298 CCDC40 CLCN7 HYDIN CCDC65 IL4R PGM3 RAG1 EDA DNAAF2 SIK3 CIITA DNAAF1 SPAG1 OFD1 RAG2 IDUA PLCG2 RSPH4A DNAI2 DNAH9 DNAI1 PGM3 ELANE DNAAF6 TCIRG1 DNAH5 CCDC114 TTC25 PLA2G7 SLC29A3 DNAJB13 RPGR CCDC103 TTC25 COX4I2 SPEF2 DNAAF5 DNAL1 MCIDAS HYDIN
Allergic rhinitis
Genes 10
IL4R COX4I2 PLA2G7 MS4A2 PLCG2 SPINK5 PGM3 PGM3 CARMIL2 SIK3